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Abstract
The nature of toxic effects exerted on neurons by misfolded proteins, occurring in a number of neurodegenerative diseases,
is poorly understood. One approach to this problem is to measure effects when such proteins are expressed in heterologous
neurons. We report on effects of an ALS-associated, misfolding-prone mutant human SOD1, G85R, when expressed in the
neurons of Caenorhabditis elegans. Stable mutant transgenic animals, but not wild-type human SOD1 transgenics, exhibited
a strong locomotor defect associated with the presence, specifically in mutant animals, of both soluble oligomers and
insoluble aggregates of G85R protein. A whole-genome RNAi screen identified chaperones and other components whose
deficiency increased aggregation and further diminished locomotion. The nature of the locomotor defect was investigated.
Mutant animals were resistant to paralysis by the cholinesterase inhibitor aldicarb, while exhibiting normal sensitivity to the
cholinergic agonist levamisole and normal muscle morphology. When fluorescently labeled presynaptic components were
examined in the dorsal nerve cord, decreased numbers of puncta corresponding to neuromuscular junctions were observed
in mutant animals and brightness was also diminished. At the EM level, mutant animals exhibited a reduced number of
synaptic vesicles. Neurotoxicity in this system thus appears to be mediated by misfolded SOD1 and is exerted on synaptic
vesicle biogenesis and/or trafficking.
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Introduction
A number of neurodegenerative diseases have been associated
with protein misfolding and aggregation, with a specific protein in
each case observed to aggregate in a particular population of
neurons. For example, in the case of amyotrophic lateral sclerosis
(Lou Gehrig’s Disease), a dominantly inherited form of this
condition, accounting for ,2% of cases, is associated with mutant
forms of the abundant cytosolic homodimeric enzyme superoxide
dismutase (SOD1), which accumulate in insoluble aggregates in
motor neurons [1–3]. Mutational studies of SOD1-linked ALS
have uncovered single residue substitutions throughout the
enzyme subunit [4], and studies in vitro indicate that the
substitutions generally destabilize the protein, disposing to
misfolding and aggregation [5–7]. It remains unknown, however,
exactly how apparent misfolding and aggregation of SOD1 exerts
toxic effects on motor neurons. Is there a central common effect
shared by the various mutant alleles that comprises a common
pathway of motor neuron injury?
Mice transgenic for a variety of mutant SOD1 alleles also
develop motor neuron disease resembling that of affected humans
[8,9], enabling a variety of pathological and biochemical studies. A
survey of pathology reported for various alleles implicates a variety
of potential physical sites of toxicity, including mitochondria,
endoplasmic reticulum, and axonal traffic. For example, abnor-
mal-appearing mitochondria have been observed in animals
transgenic for G93A and G37R SOD1 [9–11], and several
mutant SOD1’s have been coisolated with spinal cord mitochon-
dria [12–15]. Concerning ER function, an unfolded protein
response (UPR) was observed in spinal cord of G93A mice [16],
and a recent report suggests that mutant SOD1 induces this
response by binding to the ER membrane component Derlin-1,
blocking retrograde traffic of ER proteins to the cytosol for
proteasomal degradation (ERAD) at the level of ubiquitination
[17]. Concerning axonal traffic, both anterograde and retrograde
transport have been observed to be retarded in mice transgenic for
mutant SOD1 [18–24]. Which, if any, of these effects is primary to
mutant SOD1-induced motor neuron damage?
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human SOD1 in neurons in an invertebrate system to inspect for
effects on function, with the idea that this might reveal a minimal
target of the toxic effect which could ultimately be further
evaluated in the mammalian system. Such an approach has been
taken, for example, with other neurodegenerative disease-associ-
ated proteins, expressing them in Drosophila or C. elegans, including
polyglutamine repeat proteins [e.g. 25,26] and a-synuclein [e.g.
27, 28]. Here we have taken such an approach with SOD1 using
C. elegans, programming pan-neuronal expression of a mutant
version of human SOD1, G85R, that obligatorily misfolds. We
observe a locomotor defect in transgenic animals expressing the
mutant SOD1, associated with aggregation of the mutant SOD1
protein and with synaptic dysfunction, involving deficient numbers
and possibly deficient trafficking of pre-synaptic vesicles.
Results
Pan-Neuronal Expression of an ALS-Associated Mutant
Version of Human SOD1 in C. elegans Produces
Locomotor Defects Associated with Intra-Neuronal
Aggregation
To examine the effects of an ALS-associated human mutant
SOD1 on a collective of neurons in an optically accessible nervous
system, we produced transgenic C. elegans expressing G85R mutant
or wild-type human SOD1 (referred to hereafter as SOD). G85R
SOD has been identified in human cases of ALS [1], and G85R
SOD transgenic mice develop a similar disease [29]. In the latter
setting, the protein has been shown to behave as a misfolded
monomer [30]. That is, it fails to form the normal SOD
homodimer, and it lacks the normal disulfide bond that is formed
between Cys 57 and Cys 146 when the protein is properly folded.
(This disulfide bond is normally formed despite localization of
SOD to the relatively reducing cytosol). To express the wild-type
and G85R SOD proteins in as many of the 302 neurons of a C.
elegans hermaphrodite as possible, a pan-neuronal promoter, the
promoter of the C. elegans synptobrevin gene (snb-1), was used to
drive the respective wild-type and G85R human cDNAs encoding
SOD. To allow direct observation of the expressed SOD proteins,
two additional constructs were employed that join a YFP reporter
sequence via a flexible peptide linker to the C-terminus of the wild-
type or mutant SOD [31]. Multiple stable transgenic C. elegans
lines of both unfused and fused constructs were produced.
Locomotor Defects
We noticed immediately that G85R SOD transgenic animals
exhibited minimal forward movement across the culture medium
compared with normal movement of age and protein expression-
matched wild-type SOD transgenic strains (Figure 1A and Video
S1; see Figure S1 for immunoblot analysis and activity blot
analysis). The wild-type SOD transgenic animals exhibited a
forward movement speed similar to that of the parental
nontransgenic C. elegans N2 strain (Figure 1A). In addition to
severely reduced forward crawling of the mutant transgenic
animals, their side-to-side thrashing movement in liquid was also
severely affected (Figure S2 and Videos S2, S3). The rates of
forward movement of the animals transgenic for the fusion
proteins, WTSOD-YFP and G85R-YFP, likewise showed a large
difference (Figure 1B), although the mutant now exhibited
significant forward movement, and the wild-type fusion was
somewhat slower than the nonfused wild-type transgenic animals
(compare Figure 1B with 1A). These same effects were observed
on thrashing (Figure S2). Thus the addition of the YFP moiety has
effects on the mutant and wild-type SOD proteins, exerted in
opposite directions. Overall, however, even with the YFP fusion
protein, there was still markedly slower movement of the G85R
animals as compared with the wild-type (Figure 1B).
To assess whether the biological behavior of the G85R-YFP
fusion protein has any relevance to the mammalian context where
expression is associated with an identifiable clinical neuronal
disorder, G85R-YFP was produced in transgenic mice from a
human SOD genomic clone with YFP fused to the last coding
exon. This fusion produced an ALS phenotype in mice at 3–9
months of age, with the age of onset of the motor deficit depending
on copy number and expression level of the transgene (JW, GF,
KF, and ALH, unpublished). By contrast, expression-matched
wild-type SOD-YFP transgenic mice produced in parallel did not
develop disease even at ages of 2 years and beyond. Thus the
SOD-YFP fusions tested here reflect the behavior of the nonfused
counterparts in the context of production of ALS-like disease in
the mammalian setting.
An additional SOD mutant transgenic C. elegans strain, H46R/
H48Q-YFP, containing an SOD double mutant allele that blocks
copper binding by SOD and produces ALS in transgenic mice
[32], was also examined. Here it produced a movement defect less
prominent than that seen in G85R-YFP (Figure 1B).
Aggregation in Neurons of G85R-YFP Transgenic Animals
Fluorescence microscopy of transgenic C. elegans at both larval
and adult stages revealed fluorescence in many neurons in the
nerve ring (head region), the ventral nerve cord, lateral body wall,
and tail ganglia (Figure S3A). Non-neuronal fluorescence of the
spermatheca and two gonadal distal tip cells was also observed.
The character of fluorescence of neuronal cell bodies of G85R-
YFP transgenic animals differed from that of WTSOD-YFP
transgenics as exemplified by cell bodies of motor neurons along
the ventral nerve cord (Figure 2A, B). [Neuronal processes, by
contrast, did not exhibit altered fluorescence (Figure S3B).] Cell
bodies from the wild-type animals exhibited a more diffuse
cytosolic fluorescence pattern, whereas those from the G85R-YFP
Author Summary
A new animal model of the human neurodegenerative
disease amyotrophic lateral sclerosis (ALS; Lou Gehrig’s
Disease) is presented. Two percent of ALS cases result from
heritable mutations affecting the abundant enzyme
superoxide dismutase (SOD1). Such mutations have been
indicated to impair the folding and stability of the enzyme,
leading it to misfold and aggregate in motor neurons,
associated with the paralyzing disease. Here, when a
mutant form of human SOD1 was produced in neurons of
C. elegans worms, it led to a severe locomotor defect—the
worms were essentially paralyzed. The protein formed
aggregates in the neurons, including an intermediate form
of aggregate, soluble oligomers, that has been linked to
toxicity to cells. By contrast, worms expressing the normal
version of human SOD1 protein exhibited normal move-
ment and no aggregation. The movement defect was
further analyzed using chemical inhibitors and found to
result from defective function of synapses, the connections
made between neurons, and between neurons and
muscle. Finally, in a screen using RNA interference, we
observed that the worms’ aggregation and locomotor
condition was worsened when a class of molecules called
molecular chaperones, which assist protein folding in the
cell, were impaired in function. This is consistent with the
idea that misfolded SOD1 is directly involved with causing
the neuronal dysfunction.
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aggregate formation. Consistent with this, a FRAP experiment
(fluorescent recovery after photobleaching) showed very slow
recovery of fluorescence in mutant cell bodies as compared with
wild-type (see Figure S4).
Aggregates were directly observed in the mutant by EM
examination following chemical fixation (Figure 2C, D), which
revealed well-delineated electron-dense inclusions in the cytosol of
ventral nerve cord cell bodies of G85R-YFP animals (Figure 2C,
Agg.). By contrast, there were no recognizable aggregates in
WTSOD-YFP cell bodies (Figure 2D). The location of G85R-YFP
aggregates in a perinuclear position is reminiscent of aggresomes
[33] or of perinuclear structures distinct from the centrosome
known as JUNQ, involved in juxtranuclear quality control [34],
but aggregates formed in the unfused G85R animals exhibited a
more diffuse, ‘‘fluffy’’ character (Figure S5A, asterisks). When high
pressure freezing/fixation was employed on the G85R animals,
these regions were now observed as amorphous inclusions (e.g.
Figure 2E, Agg.), which at high magnification appeared to contain
loosely stacked fibrillar material (Figure 2F).
Biochemical fractionation. Biochemical analysis also revealed
insoluble SOD protein as well as soluble oligomers to be present
specifically in mutant animals. Animals were homogenized in non-
denaturing buffer, the extracts were centrifuged at
120,0006g615 min, and the supernatant and pellet fractions were
solubilized under reducing conditions and analyzed by
immunoblotting with anti-SOD antibodies. As shown in Figure 3A,
both G85R and G85R-YFP animals exhibited a substantial portion
of SOD protein in the insoluble fraction (P) whereas all of the SOD
protein in wild-type animals localized to the soluble fraction (S). The
soluble fractions of G85R-YFP and WTSOD-YFP were further
analyzed by gel filtration chromatography (under reducing
conditions), and immunoblotting of the fractions revealed the
presence of soluble oligomers specifically present in the mutant
extending in size from ,45 kDa (size of the fusion monomer) up to
,5 MDa (void volume). Such soluble oligomers are likely to be the
precursors to insoluble aggregates and have been implicated in
cellular toxicity [35–37].
Distribution. To address the distribution of neurons
containing aggregates, first we counted fluorescent aggregates in
the ventral nerve cord cell bodies (all belonging to motor neurons)
at stage L4. Individual cell bodies could not be readily assigned
due to their high density, but we observed greater than 40
aggregate-containing cell bodies out of the total of 56 cell bodies of
the ventral nerve cord. The aggregates in these cell bodies were
typically of large size, like those shown in Figure 2A. Next, a
number of individually identifiable neurons of the lateral body wall
were scored in L4 stage G85R-YFP animals for presence or
absence of a visible fluorescent aggregate (Figure 4A). This
revealed that some neurons, e.g. PVDR and SDQR, nearly always
contained an aggregate, whereas other neurons only rarely
exhibited an aggregate. Of interest in regard to such differences
is the behavior of the two neighboring lateral body wall
mechanosensory neurons, PVDR and PDER (Figure 4B). PVDR
nearly always exhibited fluorescent aggregates, usually first
observed at the L4 stage, whereas PDER was generally spared
(Figure 4B; note that PDER was present in G85R-YFP animals,
delineated by diffuse green fluorescence not clearly visible in this
image). The nature of the difference between these two neurons
that governs the different aggregation behavior is interesting to
contemplate and may relate to specific neuronal activity. More
generally, whether neurons which have sequestered misfolded
SOD-YFP into an insoluble fraction are functionally more affected
in vivo than neurons lacking aggregates, as suggested by
Matsumoto et al [31], who observed reduced viability of SOD-
YFP aggregate-containing cultured cells, or, conversely, are
protected by aggregation, as suggested by primary neuron
studies with Htt
ex1-polyQ-GFP [38], is unknown.
Concerning temporal development of aggregates, fluorescent
aggregates in the head region and ventral cord were detectable as
early as L1, while lateral body wall aggregates were not detected
until L3. Aggregation was not restricted to motor neurons, as
Figure 1. Locomotor defects in G85R and G85R-YFP transgenic C. elegans. Rates of forward movement were measured as net distance
traveled during 30 sec, divided by body length, normalized against non-transgenic L4 animals. The assay was carried out immediately after transfer to
a fresh bacterial plate and measured by videomicroscopy. N=20 for each time point; error bars=SEM. A, unfused constructs. B, YFP fusions.
Transgenic lines employed were WTSOD (line 7), G85R (line 10), WTSOD-YFP (line 51), G85R-YFP (line 18) and H46R/H48Q-YFP (line 7).
doi:10.1371/journal.pgen.1000350.g001
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that the DiI-stainable chemosensory amphid neurons in the
anterior region, as well as the stainable phasmid tail neurons,
exhibited normal DiI staining, but no green fluorescence was
observed in these cells in either mutant or wild-type animals,
leaving uncertain whether any expression of SOD-YFP occurred
in these neurons. Consistent with broad neuronal involvement,
however, additional general functions of mutant animals were
found to be affected, including survival, brood size, and rate of
development (see Figures S6, S7).
Abnormal Processes and Synaptic Function in G85R
Animals
Ventral nerve cord processes are abnormal. In further
EM studies, transverse sections of the ventral nerve cord were
prepared and the processes examined. In 4 day old adults, the
number of processes (mostly axons) in G85R animals was slightly
reduced compared with wild-type (Figure 5A). More striking,
however, were morphologic abnormalities that included reduced
diameter (compare Figure 5B, C), and reduced numbers of
organelles, both mitochondria and vesicles, within them (compare
Figure 5D, E). Some of the processes in G85R animals were also
swollen by large vesicular structures (Figure 5C). In contrast with
these abnormalities of the ventral nerve cord, the innervated body
wall muscles appeared normal, with normal sarcomeres and
subcellular organelles (not shown).
Synaptic vesicles are reduced in dorsal region. To
address whether synapses might be affected, labeling was carried
out with GFP-synaptobrevin. This protein, when expressed in DA
motor neurons, has been observed to produce a continuous
pattern of fluorescent puncta in the dorsal nerve cord, where
neuromuscular junctions are present (e.g. ref. 39). Wild-type and
G85R (unfused) transgenic animals were crossed to Punc-
129::GFP-synaptobrevin transgenic animals, and the double
transgenic progeny were examined for the number of dorsally
located green synaptic puncta that demarcate neuromuscular
junctions (Figure 6A). Whereas wild-type animals exhibited a
continuous band of such puncta, the mutant animals exhibited a
discontinuous pattern. In addition to the reduced number of
puncta (Figure 6B), their signals were also reduced. A similar
decrease in number and brightness of puncta relative to wild-type
was also observed when the fluorescent-tagged synaptic vesicle
proteins YFP-RAB-3 and synapsin-1-YFP (SNN-1-YFP) were
similarly crossed in and examined (Figure 6A). These data suggest
Figure 2. Aggregation in G85R and G85R-YFP neurons. A, B, Fluorescence analyses of G85R-YFP and WTSOD-YFP transgenic animals at stage
L4, comparing cytoplasmic fluorescence in cell bodies of ventral nerve cord. WTSOD-YFP (panel B) exhibits a diffuse pattern in cell bodies (with
noticeable nuclear exclusion) while G85R-YFP (panel A) exhibits a more discrete pattern in brighter, well defined, zones. C–F, EM analyses. Aggregate
(Agg) in the perinuclear region of a ventral cord cell body of a G85R-YFP day 4 adult animal (panel C), and normal appearance of cell body of a
WTSOD-YFP day 4 adult (panel D); Nu: nucleus. G85R (nonfused) shows fibrillar-appearing aggregate in a large nerve ring process (panels E,F). Panels
C, D from chemical immersion fixed preparation and E, F from high pressure freezing preparation.
doi:10.1371/journal.pgen.1000350.g002
Worm Model of SOD1-Linked ALS
PLoS Genetics | www.plosgenetics.org 4 January 2009 | Volume 5 | Issue 1 | e1000350that both synapse number and vesicle content in the dorsal cord is
reduced. Consistent with decreased numbers of synapses, when the
presynaptic active zone protein UNC-10 (RIM1) [40] was
examined, it exhibited a diminished number of puncta in the
mutant (Figure 6A).
A FRAP experiment was also carried out on the GFP-
synaptobrevin animals, showing slower recovery of fluorescence
at puncta in the dorsal region in G85R animals vs wild-type
(Figure 6C). This potentially reflects abnormal dynamic behavior
of synaptic vesicles in this dorsal region.
EM analysis shows a diminished number of presynaptic
vesicles. To inspect synapses at the ultrastructural level, EM
studies of the nerve ring were carried out, because this region has
the greatest concentration of synapses. Thin sections were prepared
from 4 day old adult G85R or wild-type animals using the high
pressure freezing method. The character of synapses appeared to be
affected (Figure S8). For example, in many synapses of the mutant
animals (panels C,D), there appeared to be a paucity of synaptic
vesicles which was more pronounced in the region closest to the
presynaptic density (37 of 50 synapses examined) as compared with
wild-type (panels A,B), where vesicles were densely packed in the
presynaptic region including the active zone and periactive zone (44
of 50 synapses examined). In view of the paucity of vesicles, further
EM analysis was carried out to identify whether there might be a
corresponding accumulation of vesicles in cell bodies, as occurs for
example in unc-104 kinesin-deficient animals [41], but this was not
observed. Instead, vesicles were observed in some cases to be
trapped within aggregate material.
Deficient synaptic function measured by aldicarb
assay. To assess synaptic function, the effects of the
cholinesterase inhibitor alidcarb in paralyzing wild-type or G85R
transgenic animals was measured [39,42]. Resistance to this inhibitor
can be caused by loss of cholinergic synaptic transmission. Both
G85R and G85R-YFP animals were strongly resistant to aldicarb as
c o m p a r e dw i t ht h ec o r r e s p o n d i n gw i l d - t y p ea n i m a l s( F i g u r e7 ) ,
indicating deficient synaptic function. To distinguish whether
postsynaptic function was contributing, a second compound,
levamisole, a cholinergic receptor agonist, was employed. G85R
animals displayed the same sensitivity to levamisole-induced paralysis
as wild-type (data not shown). Thus both morphologic and functional
assays point to defective presynaptic function as a proximate cause to
the locomotor defect of G85R transgenic animals.
RNAi Screen for Modifiers of Protein Aggregation—
Components that Increase Aggregation
To identify genetic modifiers of neuronal aggregation in the
G85R SOD-YFP transgenic animals, we carried out an RNAi
screen. Neurons of C. elegans are relatively resistant to RNA
interference, so alleles previously identified to enhance interfer-
ence activity, eri-1 (mg366) and lin-15B (n744), were introduced
[39]. Strikingly, the introduction of these alleles led to a significant
reduction in fluorescence from the G85R-YFP protein as
compared with the parental strain (Figure S9A), associated with
a decrease in the number of fluorescent inclusions observed in the
ventral nerve cord (Figure S9B) and with somewhat improved
movement. These results are consistent with a previous report that
lin-15B could produce silencing of multicopy transgenes [43]. We
observed that either allele alone could produce substantial
silencing of the G85R-YFP transgene, although lin-15B exerted
a greater effect. The combination of alleles proved to sufficiently
Figure 3. Biochemical analysis of SOD solubility and assembly state in transgenic animals. A, Fractionation of worm extracts into soluble
and insoluble fractions under native conditions and Western blotting. Extract was prepared by sonication and cuticle debris removed, followed by
centrifugation at 120,0006g615 min to produce soluble (S) and insoluble pellet (P) fractions. G85R and G85R-YFP exhibit substantial insoluble
material whereas none is detected in wild-type. B, Western blot analysis of fractions from gel filtration chromatography of soluble fraction, showing
soluble G85R-YFP oligomers extending from monomer-size up to the void volume. WTSOD-YFP, by contrast, shows only lower molecular weight
species. Numbers above the blot panels indicate the size in kDa of standard proteins chromatographed on the same column; Vo=void volume,
corresponding to ,5 MDa size.
doi:10.1371/journal.pgen.1000350.g003
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degree that could allow for a ‘‘dynamic’’ range of effects of RNAi
screening, i.e. both reduction and enhancement of green
fluorescence patterns reflecting aggregation would be detectable.
A bacterial feeding library was employed for RNAi testing.
Collectives of animals at all stages were transferred onto feeding
plates and visually examined by multiple observers after 3–6 days
for changes in the number and intensity of fluorescent aggregates
in the nerve ring and ventral nerve cord as compared with the
strain fed bacteria with an empty vector.
In the general case of observing decreased fluorescent
aggregates when animals were placed on a particular interfering
bacterial strain, the development of the animals was generally also
slowed and viability in many cases reduced, reflecting likely effects
on general health or on general gene expression, and these
interfering RNAs were not studied further. There was one
exception to this, involving an interfering RNA for a ubiquitin
specific protease, where fluorescent aggregation was reduced and
viability somewhat improved, and this gene is under further study.
In the general case of animals with increased fluorescent
aggregates on a particular interfering bacterial strain, these
animals generally exhibited larger numbers of fluorescent
inclusions and diminished locomotion. There were 88 such hits
(Table S1). 7 of these appeared likely to suppress eri-1; lin-15B
action and were not studied further (see last entries in Table S1),
while the remaining 81 hits were categorized into 10 groups
(Table 1). The largest group of well-annotated hits comprised
molecular chaperones and quality control components, amounting
to about a quarter of the hits. These are discussed below. The
other large group, of about the same size, comprised a collective of
uncharacterized gene products.
To independently confirm RNAi hits in the parental genetic
background, loss-of-function alleles were obtained for 12 hits of
interest and were crossed with the parental G85R-YFP strain. 11
out of 12 of these enhanced the inclusion phenotype of G85R-
YFP. For example, heat shock factor 1 (HSF1), which transcrip-
tionally regulates a number of stress components [44], registered
very strongly in the RNAi screen in increasing aggregate
Figure 4. Distinct neuronal pattern of aggregation in G85R-YFP animals. A, Involvement of selected lateral neurons. Mid-L4 G85R-YFP
animals were scored; N=21. Note that neuronal function and birth time do not appear to correlate with aggregate formation. B, PVDR generally
presents with a well demarcated fluorescent inclusion whereas PDER, lying next to it, is usually unaffected in G85R-YFP animals. Arrows point to
cytosolic aggregates.
doi:10.1371/journal.pgen.1000350.g004
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into G85R-YFP, a strong increase in aggregate formation was
observed (Figure S10A), and locomotion of these animals was
substantially decreased as compared with either parental strain
(Figure S10B).
Multiple interference hits of strong magnitude were observed in
a number of pathways (Table 2), indicating that these pathways
are likely playing a role in preventing aggregation of the misfolded
G85R-YFP protein or facilitating its turnover. For example, hits of
a collective of chaperone components registered strong increases of
aggregation, including an Hsp110 (C30C11.4), a DnaJ (A2) (dnj-
19), an Hsp70 (stc-1), and a neuron specific Hsp16 (F08H9.4).
Three of these were validated as strongly increasing aggregation
when mutant alleles were crossed with G85R-YFP. Two hits were
identified in the ubiquitin-mediated turnover pathway at the level
of E3 ligase SCF complexes, SEL-10, an F-box protein, and RBX-
1, a RING finger protein, the latter confirmed with the ok782
knockout allele. Three hits were also observed in the sumoylation
pathway by the RNAi screen, uba-2, encoding the E1 enzyme that
activates SUMO, ubc-9, which encodes one subunit of the E2
SUMO-conjugating heterodimer, and an E3 SUMO-ligase
component gei-17 (homologous to PIAS1). In validation of the
interference effects, an allele of SUMO, smo-1 (OK359), increased
aggregation when crossed into the parental G85R-YFP strain. The
latter hits raised the question of whether G85R-YFP is itself
sumoylated, and this is under study. In addition, three components
involved with redox regulation were identified, PDI-2, an
orthologue of a human thioredoxin domain-containing protein
(C30H7.2), and BLI-3, a dual oxidase with both a peroxidase
domain and a superoxide-generating oxidase domain.
Other pathways were also identified through strong effects of
interference. For example, a hit in the TGFb component DBL-1
was confirmed by the allele nk3. DBL-1 is expressed in neuronal
cells, e.g. in the ventral cord, has recently been implicated in
GABAergic synaptic transmission [45], and has been shown to
affect both body size and male tail development [46]. Notably, in
Figure 5. Ventral nerve cord is affected in 4 day old adult G85R animals – fewer and smaller diameter processes and lack of
organelles. A, Number of neuronal processes is mildly reduced. Transverse sections of transgenic animals were prepared and examined by EM, and
the number of neuronal processes in the main bundle of the ventral nerve cord was determined. N=9. (Error bars indicate SEM.) B–E, Representative
cross-sections of WTSOD and G85R animals at two levels of magnification, with white dashed lines in B, C denoting the boundaries of the main
bundle of processes. The diameter of processes was reduced, and the number of organelles including mitochondria (m) and synaptic vesicles (arrows)
was greatly reduced in G85R.
doi:10.1371/journal.pgen.1000350.g005
Worm Model of SOD1-Linked ALS
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effects on axon outgrowth and protection from excitotoxicity [e.g.
47]. A hit of the dopamine transporter DAT-1 was confirmed with
allele tm903. A link between neuronal activity and aggregation in
the cases of GABAergic and dopaminergic transmission thus seems
a consideration but requires further study. In the DNA
replication/repair pathways, interference with top-1, the gene for
topoisomerase 1, had a very strong effect, equivalent to the strong
effect of hsf-1 interference. How such action could figure into
aggregation behavior remains unclear. Similarly, interference of
div-1, a subunit of the DNA polymerase a/primase complex,
increased aggregation. Also a strong effect was observed with
interference of pha-4, a FoxA transcription factor, implicated in
calorie-restriction-mediated longevity, at least in part by regulating
endogenous C. elegans SOD enzymes [48].
Discussion
Neuronal Presynaptic Dysfunction in G85R SOD
Transgenic Worms
We have described here that pan-neuronal expression of a
human ALS-associated mutant SOD in C. elegans produces
Figure 6. Dorsal nerve cord of G85R at L4 stage exhibits diminished numbers and brightness of puncta of fluorescent presynaptic
markers and diminished fluorescence recovery of GFP-synaptobrevin after photobleaching. A, Three different fluorescent protein-
tagged synaptic proteins, synaptobrevin (SNB-1), RAB-3, and synapsin-1 (SNN-1), and one tagged presynaptic active zone protein, Rim1, were
examined in WTSOD and G85R transgenic worms. Anterior portion of the dorsal cord is shown. In all cases there was a reduced number of puncta in
the mutant animals. This was quantitated in panel B for GFP-SNB-1 animals, examining 10 of each genotype at L4 stage. Puncta were counted along a
50 micron distance and normalized to total body length. The number was reduced in the mutant animals, p=0.0004. Error bars=SEM. Panel C,
fluorescent recovery after photobleaching (FRAP) of GFP-synpatobrevin. Left, example of photobleaching of dorsal cord. Right, recovery of
fluorescence plotted as function of time. Mid-L4 animals were subject to photobleaching, covering an area of 1 mm surrounding the dorsal punctum
of interest, and fluorescence was recorded thereafter. Average intensity was normalized to the pre-bleaching intensity. G85R showed significantly
slower recovery. N=8 for each genotype. Error bars are SEM.
doi:10.1371/journal.pgen.1000350.g006
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gation in neuronal cell bodies. By contrast, a wild-type human
SOD produced neither locomotor defects nor aggregation.
Further testing indicated that the human SOD mutant, G85R,
unable to fold properly and producing both soluble oligomers and
aggregates, appears to produce neuronal dysfunction in C. elegans
at the presynaptic level. This was indicated by three types of
observation. First, there was a reduced number and brightness of
puncta of fluorescently-labeled synaptobrevin, RAB-3, and
synapsin, as well as of the presynaptic active zone protein RIM1
in the dorsal nerve cord in transgenic G85R animals as compared
with wild-type SOD transgenic animals. Second, mutant trans-
genic animals but not wild-type exhibited resistance to aldicarb
paralysis, consistent with deficient acetylcholine release at
cholinergic synapses in the mutant. Third, EM studies on a small
number of animals revealed paucity of vesicles in the presynaptic
region of nerve ring synapses of the mutant animals. In addition,
EM showed reduced numbers of vesicles and mitochondria in
ventral nerve cord processes (axons) of transgenic mutant animals.
In contrast with the foregoing findings pointing to presynaptic
dysfunction, there was a lack of postsynaptic effects. The
cholinergic agonist levamisole produced the same efficient
paralysis of both mutant G85R and wild-type SOD transgenic
animals. In addition, EM inspection of muscle revealed normal
morphology.
The putative presynaptic defect could result, in the first
instance, from defective biogenesis, axonal transport, or recycling
of synaptic vesicles. The diminution of vesicles in dorsal and
ventral nerve cord processes and their sparsity in the presynaptic
regions as demonstrated from the EM and fluorescence studies
suggest that biogenesis or transport is affected. Because accumu-
lations of vesicles were not detected in cell bodies, it seems less
likely that transport is affected. Yet the failure of recovery of the
GFP-synaptobrevin fluorescence following photobleaching could
be consistent with an ongoing transport or recycling defect.
Further studies will be required to resolve the steps affected.
Excitingly, effects of expression of human SOD1 on synaptic
transmission in another invertebrate system have recently been
reported. Watson et al [49] observed that expression of human
SOD1 (wild-type or mutant) in motor neurons of Drosophila
produced an age-progressive climbing defect that was associated in
electrophysiological studies, stimulating muscle through the giant
fiber circuit, with progressive loss of muscle response during high
frequency stimulation.
Presynaptic effects have also been observed in several contexts in
C. elegans expressing a number of other neurodegeneration-
associated proteins. Animals transgenic for both wild-type and
FTDP-associated mutant forms of tau presented with locomotor
defects, associated with aldicarb resistance (and levamisole sensitiv-
ity), followed by appearance of macroscopic aggregates and then
apparent neuronal loss [50]. Animals transgenic for a-synuclein
exhibited locomotor defects when any of a number of synaptic
proteins were knocked down, associated with aldicarb resistance
and levamisole sensitivity [28]. In contrast with these studies,
however, the studies of SOD1 presented here indicate a direct and
specific effect of the mutant G85R SOD1 on presynaptic function.
Misfolding and Aggregate Formation and Linkage to
Locomotor Defect
So far it is not evident how or whether the presence of G85R-
SOD aggregates in cell bodies of specific neurons, comprising a
Figure 7. Aldicarb paralysis assay of SOD transgenic strains. G85R and G85R-YFP transgenic animals of L4 stage are relatively resistant to
aldicarb. A, Comparison of WTSOD and G85R transgenic animals at various times after exposure to aldicarb, measuring percentage that fail to exhibit
movement upon physical prodding in the head region. B, Comparison of WTSOD-YFP and G85R-YFP animals for percent exhibiting aldicarb paralysis.
Error bars are SEM.
doi:10.1371/journal.pgen.1000350.g007
Table 1. Summary of 81 RNA interference hits that worsened
aggregation.
Protein chaperones, turnover, and modification 22 27.2%
Redox 3 3.7%
Signal transduction 7 8.6%
Transcription, RNA processing 6 7.4%
Metabolism 6 7.4%
DNA replication and repair 4 4.9%
Extracellular matrix 2 2.5%
Translation 2 2.5%
Intracellular trafficking 2 2.5%
Uncategorized 27 33.3%
doi:10.1371/journal.pgen.1000350.t001
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directly relates to the apparent presynaptic defect. We note,
however, that the degree of locomotor defect correlates roughly
with the degree of aggregation observed. For example, for the
G85R-YFP transgene, out of multiple stable integrant lines, those
with the highest level of fluorescence and greatest level of
aggregation exhibited the strongest locomotor defect. Thus, either
the aggregates themselves or perhaps the apparent precursors,
soluble oligomers (Figure 3B), may be directly responsible for the
presynaptic defect. The defect could come at the level of physical
interactions of oligomers or aggregates either directly with synaptic
vesicles themselves or with soluble or cytoskeletal components that
are involved with vesicle biogenesis and traffic. A recent study
producing pan-neuronal expression of dimeric versions of human
wild-type and G85R SOD1 in C. elegans also observed locomotor
defects associated with aggregation, but, in contrast to the direct
correlation above, observed that a heterodimeric G85R-WTSOD-
GFP molecule, while producing less aggregation than G85R-
G85R-GFP, led to a greater paraquat-induced reduction of animal
survival [51]. Thus in the context of a heterodimer, residual SOD
enzymatic activity may contribute to toxicity.
Lack of Neuronal Cell Death
Notably, despite evident protein aggregation and synaptic
dysfunction, neurons in the mutant animals studied here were
not subject to cell death, even during later adult life. This
resembles the observation in the recent report of Watson et al [49]
where human SOD1 expressed in Drosophila motor neurons
produced both focal SOD protein accumulation and measurable
electrical dysfunction but no observable cell death. Similarly, in
earlier studies of C. elegans PLM neurons transgenic for
polyglutamine expansion, touch sensitivity function was abolished
but cell death did not occur [52]. This lack of cell death may either
relate to the state of disease progression or be a function of the
invertebrate neuronal systems themselves. For example, concern-
ing stage of disease, in the mammalian context, SOD1-affected
motor neurons appear likely to be functionally affected for a
period of time before being subject to cell death. In C. elegans or
Drosophila, by contrast, the trajectory may not extend sufficiently in
time to produce cell death, albeit that added insults such as
oxidative toxicity [50] may be capable of producing cell death.
Alternatively, these systems may differ from that of mammals. C.
elegans has, for example, a limited number of glia, and they may
not function as in the mammalian context to hasten death of
affected neurons [53–55]. Alternatively, the absence of cell death
could be a function of a different neuronal response to chronic
exposure to misfolded protein as compared with mammalian
neurons.
Proteostatic Protection from Misfolded SOD in C. elegans
Neurons
The RNA interference screen conducted here, examining
relative levels of G85R-YFP protein aggregation in relation to
knockdown of various gene products, validated in many cases by
crosses with corresponding mutant alleles (Table 2), provided
evidence that a proteostatic network similar to that present in body
wall muscles of C. elegans [56,57] and elsewhere [44] is operative in
C. elegans neurons. Whether it is induced in response to mutant
Table 2. Selected genes whose inactivation strongly aggravates formation of SOD-YFP neuronal inclusions
1.
CATEGORY GENE FUNCTION
2RNAI
SCORE
3ALLELE
SCORE
Chaperone/quality control hsf-1 (Y53C10A.12) Heat shock transcription factor 5 sy441 ++
C30C11.4 homolog to human apg-1 (a heat shock 110 kDa protein) 3 gk533 ++
dnj-19 (T05C3.5) homolog to DnaJ subfamily A member 2 3 gk649 ++
F08H9.4 neuron-specific HSP16 3 ok1976 ++
stc-1 (F54C9.2) member of HSP70 superfamily (microsome associated) 3
Protein turnover sel-10 (F55B12.3) member of the CDC4/CUL-1 family of ubiquitin ligases 3
rbx-1 (ZK287.5) RING box protein RBX1, a subunit of the SCF ubiquitin-ligase complex 2 ok782 +
W07G4.4 Predicted aminopeptidase 4
Protein modification uba-2 (W02A11.4) sumo activating enzyme 5
ubc-9 (F29B9.6) sumo conjugating enzyme 4
gei-17 (W10D5.3) Homologous to E3 SUMO-protein ligase PIAS1 3
Redox bli-3 (F56C11.1) dual oxidase 3 e767 ++
pdi-2 (C07A12.4) Protein disulfide isomerase 2 gk375 ++
C30H7.2 thioredoxin domain-containing protein precursor 2
Signal transduction dbl-1 (T25F10.2) member of the TGFb superfamily 3 nk3 +
Dopamine metabolism dat-1 (T23G5.5) plasma membrane dopamine transporter 3 tm903 +
Dna replication & repair top-1 (M01E5.5) DNA topoisomerase I 5
div-1 (R01H10.1) homolog of the B subunit of the DNA polymerase alpha-primase complex 3 or148 ++
Transcription H43I07.2 RNA polymerase I and III, subunit RPA40/PRC40 3
Longevity factor pha-4 (F38A6.1) FoxA transcription factor 4
120 genes out of the 88 hits from the screen are listed here.
2RNAi scores range from 1 to 5, with 5 representing the strongest increase of the G85R-YFP inclusions, and 1 a discernible increase.
3Alleles are loss-of-function mutations that have been bred to homozygosity in the strain carrying the G85R-YFP transgene; ‘‘+’’ represents moderate increase of the
inclusion profile, and ‘‘++’’ strong increase.
doi:10.1371/journal.pgen.1000350.t002
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level of expression of some or all members of the network could be
protective remains to be tested. Two transcriptional regulators that
lie at the top of such a network were identified, HSF-1 and PHA-
4/FoxA, which have a broad range of targets in, for example,
chaperone pathways [44] and redox regulation [48], respectively.
Components within the network were also identified, including
chaperones, an E3 ligase, and redox components. Additional
components had effects on aggregation but their mechanism of
action remains unclear, including SUMO, the TGF-b homologue,
DBL-1, expressed mainly in neurons, and two components of
DNA maintenance, topoisomerase I and a subunit of pola/
primase complex, implicating DNA integrity in the response.
Notably absent from both the interference screen and from EM
studies was evidence for involvement of the autophagy system.
Consistent with this, administration of rapamycin was without
effect on the extent of aggregation (data not shown).
Relation of the Worm G85R SOD-Induced Phenotype to
G85R SOD-Associated ALS in Mouse
Do the phenotypic properties observed here bear any relation to
mammalian disease induced by expression of mutant SOD1? Could
the transgenic C.elegans inform usefully about mammalian disease? As
mentioned, the G85RSOD-YFP fusion protein expressed in mice
indeed produces an ALS-like disease whereas WTSOD-YFP fusion
produces no ill effect. Interestingly, the presynaptic effects observed
here with the G85R transgenic C. elegans may have a parallel in
mutant G85R SOD transgenic mice, as reported recently by Caroni
and colleagues [58], who examined motor neuron axons and NMJs
in hind limb muscle of mutant transgenic animals of varying age [see
also 59]. In vulnerable motor neuron axons (FF and FR), they
observed at early time (7 months of age; 2 months before end-stage)
localized synaptic vesicle accumulation associated with diminished
overall density of vesicles, reflecting apparent stalling of vesicle traffic,
followed at a later stage by severe loss of synaptic vesicles associated
with loss of presynaptic active zone markers. The findings at later
time generally agree with the observations here in dorsal cord of our
G85R C. elegans, where both fluorescent synaptic vesicle protein
markers and an active zone marker (RIM1) appear to be reduced
(Figure 6). The nature of the vesicle trafficking defect in either setting
remains to be elucidated. Does it reflect failure of vesicles to be
produced in the first instance, as suggested by the lack of organelles in
ventralcord processes here (Figure 5), and/or is ita block of recycling,
as might be suggested by the FRAP analysis of GFP-synaptobrevin
(Figure 6C)? Is it a direct effect of mutant SOD, forming physical
association with synaptic vesicles? Or is it a secondary effect,
mediated e.g. via the motor/cytoskeletal trafficking system? Ques-
tions concerning both the basis to vesicular defects and the overall
pathway of toxicity of mutant SOD protein remain to be resolved.
Materials and Methods
DNA
The C. elegans snb-1 promoter, a PCR-amplified genomic DNA
segment extending from minus 3021 bp to just upstream of the
SNB start codon, was inserted in place of the unc-54 enhancer/
promoter in the plasmid pPD30_38 (Fire Lab Vector Kit,
Addgene Inc., Cambridge, MA), and the various human SOD
cDNA-containing segments were then adjoined. SOD mutations
were generated by PCR, and the derived coding sequences
confirmed by sequencing them in entirety. Fusion constructs
joining human SOD with YFP via a linker segment (LQLQASAV)
were kindly provided by Dr. R. Morimoto, Northwestern
University [31].
C. elegans Strains and Methods
The N2 Bristol strain of C. elegans was used as the wild-type
strain. Standard culturing and genetic methods were used [60].
Animals were maintained at 20uC unless otherwise indicated.
Mutant strains obtained from the Caenorhabditis Genetics Center
(CGC), the National Bioresource Project in Japan, and the lab of
Joshua Kaplan are listed in Suppl. Table 2. Germline transfor-
mation was performed by injecting DNA solution containing
20 ng/ml of an SOD construct and 5 ng/mlo fmyo2::GFP into
hermaphrodite gonads [61]. Multiple extrachromosomal lines
were established based on the fluorescent markers. They were
further treated with trimethylpsoralen/UV to generate integrated
lines that stably expressed the transgenes. At least three
independent stable lines were produced for each variant, and
each line was backcrossed with the N2 strain four times. The
transgenic SOD and SOD-YFP lines used in these studies are
designated in the legend to Figure 1. nuIs152 has the transgene
Punc-129::GFP-snb-1 [39]. nuIs168 has the transgene Punc-
129::YFP-Rab-3 [62]. nuIs163 and nuIs165 strains containing
Punc-129::snn-1-YFP and Punc-129::unc-10-GFP were the kind gift
of Joshua Kaplan [63].
Microscopy
For high resolution imaging, animals were immobilized with
levamisole and examined by either differential interference
contrast (DIC) or fluorescence with an Olympus IX81 microscope
equipped with spinning disk confocal illumination. For fluores-
cence recovery after photobleaching (FRAP), a laser confocal
microscope was used (Zeiss LSM510 META).
For transmission electron microscopy, animals were prepared
by conventional two-step chemical immersion fixation or high-
pressure-freezing [64,65]. Serial thin sections were prepared and
post-stained with heavy metals. At least four animals of each
genotype were analyzed using a Tecnai 12 Biotwin at 80 kV.
Locomotion Analysis
A video-based assay was used to assess the locomotion speed of
C. elegans. Animals were transferred to a plate with a fresh bacterial
lawn on which movement tracks could be traced. Immediately
upon release, worms exhibit a maximum movement response for a
short duration. A 30 second movie was shot for each worm, and
the ratio of the movement distance to the body length, measured
by the NIH ImageJ software, was used as a movement index (see
Video S1).
Aldicarb Sensitivity Assay
Mid L4 animals were transferred to freshly made NGM agar
plates without bacterial food containing 1 mM aldicarb, and at
different time points the animals were prodded on the nose to
determine whether they had reached complete paralysis [42]. An
identical experiment with 1 mM levamisole was also performed.
Protein Analysis
To assess solubility of SOD protein, animals were disrupted by
sonication on ice in 0.5 ml extraction buffer (PBS, 1 mM EDTA,
1 mM EGTA, 1 mM TCEP, with half a tablet of Complete Mini
protease inhibitor cocktail (Roche)) and left on ice for 10 min to
allow large debris, including cuticle, to sediment. The supernatant
fraction was then centrifuged in a Beckman TLA-100 rotor at
53,000 rpm (.120,0006g) for 15 min at 4uC. Pellets were washed
once by resuspension in the extraction buffer and sedimentation.
Supernatant and SDS-solubilized pellet fractions were analyzed in
SDS-PAGE under reducing conditions. Supernatant fractions
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chromatography on a Superose 6 gel filtration column (GE
Healthcare) and eluted with PBS supplemented to 0.1 mM TCEP
at 0.5 ml/min. Individual fractions (0.5 ml) were examined by
SDS-PAGE and Western blotting. For Western analysis, antibod-
ies to human SOD1 (SOD-100, Stressgen, Canada), antibodies
raised in rabbits against purified YFP (Cocalico), or antibodies to
actin (C4, MP Biomedicals, Inc., Aurora, Ohio) were used.
RNAi Feeding Screen and Further Tests with Loss-of-
Function Alleles
An RNAi feeding library of 16,757 bacterial clones was
employed for screening (GeneService, Cambridge, UK). Animals
at mixed ages were screened in 96-well plates at 15uC as described
[66]. ‘‘Hits’’ were identified by an increased number and intensity
of fluorescent neuronal inclusions using a Leica fluorescence
stereoscope with a 2.06 PLANAPO lens. All positives were
subjected to secondary screening at both 15uC and 20uC in 6-well
plates. The identities of all positive RNAi clones were confirmed
by DNA sequencing of the plasmid insert. For selected hits, where
loss-of-function alleles were available, the corresponding strains
were crossed to the G85R-YFP parental strain (line 8). The
genotypes of the product strains were verified by PCR or PCR/
DNA sequencing and the phenotypes studied.
Supporting Information
Figure S1 Amount and activity of human SOD expressed from
a pan-neuronal promoter in transgenic C. elegans strains. A, Top,
Immunoblot probed with anti-human SOD1 antibody (no cross-
reaction with C. elegans SOD); Bottom, identical amounts of sample
probed with anti-actin antibody in blot of gel identical to that in
top panel. NTg, non-transgenic Bristol N2 strain of C. elegans.
10 mg of total protein was applied for each lane. Transgenic lines
were WTSOD1 (line 23), G85R (line 10), WTSOD1-YFP (line
51), H46R/H48Q-YFP (line 7), and G85R-YFP (line 18). Note
that G85R routinely migrates faster than WTSOD. This effect is
also present, although less apparent, for the fusion proteins. B,
Top, In-gel activity assay [67] carried out on native gel in which
soluble extract (120,0006g615 min) of worm strains had been
fractionated. 100 mg protein was applied to each lane. Activity of
wild-type human SOD1 (and its fusion), but not that of the mutant
SOD1’s was observed (no activity of endogenous C. elegans SOD
was detected). Bottom, Western blot of denaturing gel loaded with
one-tenth the amount of sample as that in top panel, probed with
anti-human SOD1 antibody. In both cases, only the relevant
section of the gel or blot is shown.
Found at: doi:10.1371/journal.pgen.1000350.s001 (0.69 MB TIF)
Figure S2 Thrashing rate of transgenic C. elegans strains. L4
animals were transferred to a drop of M9 buffer at 20uC and after
1 min of adaptation the number of body bends was counted for
1 min. N=37. Error bars are SEM.
Found at: doi:10.1371/journal.pgen.1000350.s002 (0.27 MB TIF)
Figure S3 Expression pattern of Psnb1::human SOD1-YFP in
C. elegans assessed by fluorescence imaging. A, Lateral view of
stably-transformed WTSOD1-YFP transgenic L4 animal showing
expression of fluorescent protein in nerve ring region, in ventral
nerve cord, in dorsal nerve cord, as well as in lateral neuronal cell
bodies, and in tail region. Arrow indicates position at which lateral
wall neuron shown in panel B is situated. B, Lateral view of ALM
neuron in lateral wall of L4 animals. Head of worm is to left.
Arrows point to processes and arrowhead points to aggregate in
cell body of the G85R-YFP neuron.
Found at: doi:10.1371/journal.pgen.1000350.s003 (0.88 MB TIF)
Figure S4 Fluorescence recovery after photobleaching (FRAP)
of ventral nerve cord cell bodies of G85R-YFP and WTSOD1-
YFP transgenic C. elegans. Black circle denotes location of
photobleaching. n, nucleus.
Found at: doi:10.1371/journal.pgen.1000350.s004 (1.09 MB TIF)
Figure S5 Diffuse aggregate formation in the cytosol of cell
bodies of ventral nerve cord of G85R transgenic animals but not in
WTSOD1 transgenics. Altered appearance of cytosol (asterisks),
with ‘‘fluffy’’ character and with no discernible organelles in this
section of a neuron cell body of a G85R animal (left), distinct from
normal cytosol in cell body of a WTSOD1 transgenic animal
(right). Note that the fluffy inclusion has pushed the nucleus away
from the center of the cell body, similar to the position of the dense
aggregate in Figure 2C. Day 4 adults were prepared by chemical
immersion fixation. Scale bar 1 mm.
Found at: doi:10.1371/journal.pgen.1000350.s005 (1.77 MB TIF)
Figure S6 Survival curves and brood sizes of transgenic animals.
A, B Survival of animals was followed from mid-L4, with death
determined by failure to respond to mechanical prodding. N=45
for each genotype. C, D Brood size was determined by counting
eggs laid during the lifetime of hermaphrodite. Lines used were
WTSOD1 (line 23), G85R (line 10), WTSOD1-YFP (line 51), and
G85R-YFP (line 18). N=24 for each genotype. Error bars are
SEM. All animals were cultured under standard conditions at
20uC. The presence of G85R mutation affects these parameters,
with a more severe effect of the G85R-YFP fusion.
Found at: doi:10.1371/journal.pgen.1000350.s006 (0.63 MB TIF)
Figure S7 Rate of larval development of transgenic animals.
Individual animals at L1 stage were selected and scored for
developmental progression after 40 hr and 60 hr. G85R-YFP
fusion animals were strongly delayed in development compared
with G85R. N=30 for each genotype; error bars=SEM.
Found at: doi:10.1371/journal.pgen.1000350.s007 (0.76 MB TIF)
Figure S8 Paucity of pre-synaptic vesicles in G85R transgenic
animals. Representative transverse sections of pharyngeal nerve
ring from day 4 adult animals prepared by high-pressure-freezing
method, with white arrows pointing to presynaptic density from
the postsynaptic side. Note the paucity of presynaptic vesicles
overall, and stronger depletion close to the presynaptic density in
the G85R animals (panels C,D) compared with robust numbers of
presynaptic vesicles in WTSOD animals (panels A,B). Scale bar,
500 nm.
Found at: doi:10.1371/journal.pgen.1000350.s008 (1.39 MB TIF)
Figure S9 The double mutant background eri1;lin-15B that
facilitates RNA interference in neurons reduces the expression/
fluorescence of G85R-YFP, with corresponding reduction of the
number of fluorescent inclusions. A, G85R-YFP transgenic
animals of different stages with or without presence of eri-
1(mg366); lin-15B(n744) were imaged. L1 and L2, whole animal
views. L4 and adult, ventral cord region is shown. Bright puncta
along ventral cord correspond to fluorescent inclusions in cell
bodies. B, numbers of fluorescent inclusions in ventral nerve cord
on successive days in the same animals. N=18 for each genotype;
error bars=SEM.
Found at: doi:10.1371/journal.pgen.1000350.s009 (0.73 MB TIF)
Figure S10 Effects of several mutant alleles on aggregation and
locomotion of G85R-YFP animals. A, The hsf-1 loss-of-function
allele sy441 causes an increase of aggregation. Nerve ring and
anterior ventral cord of L1 stage animals are shown. B, sy441 and
mutant alleles of dbl-1 and div-1 produce defective forward
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shown) was set to 100%.
Found at: doi:10.1371/journal.pgen.1000350.s010 (0.84 MB TIF)
Table S1 RNAi screening hits.
Found at: doi:10.1371/journal.pgen.1000350.s011 (0.10 MB
XLS)
Table S2 Strains.
Found at: doi:10.1371/journal.pgen.1000350.s012 (0.06 MB
DOC)
Video S1 Crawling movement defects in C. elegans expressing
mutant SOD1 in neurons. A representative G85R-YFP hermaph-
rodite and a WTSOD-YFP control were transferred to a fresh
plate with OP50 E. coli, and their movements were video-
recorded. Animals are day 2 adults.
Found at: doi:10.1371/journal.pgen.1000350.s013 (11.14 MB
MOV)
Video S2 Thrashing movement. Thrashing movement defects in
C. elegans expressing mutant SOD1 in neurons. A representative
G85R hermaphrodite (S2) and a WTSOD control (S3) were
transferred to M9 buffer, and their thrashing was video-recorded.
Animals are at the L4 stage.
Found at: doi:10.1371/journal.pgen.1000350.s014 (2.87 MB
MOV)
Video S3 Wild-type thrashing. Thrashing movement defects in
C. elegans expressing mutant SOD1 in neurons. A representative
G85R hermaphrodite (S2) and a WTSOD control (S3) were
transferred to M9 buffer, and their thrashing was video-recorded.
Animals are at the L4 stage.
Found at: doi:10.1371/journal.pgen.1000350.s015 (2.99 MB
MOV)
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